Small molecule · Inhibitor of VEGFR-2 (kinase insert domain receptor) (KDR) · developed by Bristol-Myers Squibb
Phase 2Most advanced trial (none active)
1Registered trials
What is Brivanib?
Brivanib is a pyrrolotriazine-based small molecule that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), a tyrosine kinase receptor expressed mainly on vascular endothelial cells. By blocking VEGFR-2, it is intended to inhibit VEGF-stimulated endothelial cell migration and proliferation and thereby tumor angiogenesis. It is studied in hepatocellular carcinoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
BMS-540215
Drug type
Small molecule
Targets
VEGFR-2 (kinase insert domain receptor) (KDR)
Mechanism
Inhibitor of VEGFR-2 (kinase insert domain receptor) (KDR)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.